CA3226393A1 - Water soluble prodrug, conjugates and uses thereof - Google Patents

Water soluble prodrug, conjugates and uses thereof Download PDF

Info

Publication number
CA3226393A1
CA3226393A1 CA3226393A CA3226393A CA3226393A1 CA 3226393 A1 CA3226393 A1 CA 3226393A1 CA 3226393 A CA3226393 A CA 3226393A CA 3226393 A CA3226393 A CA 3226393A CA 3226393 A1 CA3226393 A1 CA 3226393A1
Authority
CA
Canada
Prior art keywords
moiety
compound
conjugate
oligo
auristatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3226393A
Other languages
English (en)
French (fr)
Inventor
Doron Shabat
Ronit Satchi-Fainaro
Stanley SWEENEY-LASCH
Carl Deutsch
Nir BERGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Ramot at Tel Aviv University Ltd
Original Assignee
Merck Patent GmbH
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH, Ramot at Tel Aviv University Ltd filed Critical Merck Patent GmbH
Publication of CA3226393A1 publication Critical patent/CA3226393A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3226393A 2021-07-28 2022-07-20 Water soluble prodrug, conjugates and uses thereof Pending CA3226393A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL285208 2021-07-28
IL28520821 2021-07-28
PCT/IL2022/050782 WO2023007481A1 (en) 2021-07-28 2022-07-20 Water soluble prodrug, conjugates and uses thereof

Publications (1)

Publication Number Publication Date
CA3226393A1 true CA3226393A1 (en) 2023-02-02

Family

ID=85086377

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3226393A Pending CA3226393A1 (en) 2021-07-28 2022-07-20 Water soluble prodrug, conjugates and uses thereof

Country Status (7)

Country Link
EP (1) EP4377292A1 (https=)
JP (1) JP2024532677A (https=)
CN (1) CN117999254A (https=)
AU (1) AU2022318483A1 (https=)
CA (1) CA3226393A1 (https=)
IL (1) IL310354A (https=)
WO (1) WO2023007481A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4566631A1 (en) * 2023-12-06 2025-06-11 Heidelberg Pharma Research GmbH New antibody drug conjugate as well as methods of production and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701128YA (en) * 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
CN120682290A (zh) * 2017-07-04 2025-09-23 尹图赛利有限公司 包含可裂解接头的化合物及其用途
JP7708662B2 (ja) * 2018-10-24 2025-07-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法

Also Published As

Publication number Publication date
CN117999254A (zh) 2024-05-07
EP4377292A1 (en) 2024-06-05
IL310354A (en) 2024-03-01
AU2022318483A1 (en) 2024-02-22
JP2024532677A (ja) 2024-09-10
WO2023007481A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
Nakada et al. Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
JP7620991B2 (ja) 標的送達及び活性化した免疫刺激性複合体の調製と使用
JP6854759B2 (ja) 腫瘍微環境によって特異的活性化する小分子標的結合体およびその使用
US5892043A (en) Camptothecin derivatives
JP5313867B2 (ja) カンプトテシン−細胞透過性ペプチド複合体及びそれを含む医薬組成物
JP6539729B2 (ja) ペプチド−薬物複合体
JP7425606B2 (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
JP2018512376A (ja) 抗体薬物コンジュゲート
CN102448469A (zh) 包括具有可变的释放速率的连接物的聚缩醛(酮)-药物共轭物
NO20024421L (no) Polyglutaminsyre-camptothecin-konjugater og fremgangsmÕte for fremstilling av disse
JPWO1999061061A1 (ja) 薬物複合体
Batisse et al. A new delivery system for auristatin in STxB-drug conjugate therapy
JP2020533269A (ja) 抗体−薬物複合体およびその使用
CA3226393A1 (en) Water soluble prodrug, conjugates and uses thereof
CN105131039B (zh) 一种喜树碱类磷脂化合物、其药物组合物及应用
CN116036303B (zh) 一种抗体-药物偶联物及其制备方法和应用
CN109790178A (zh) 新颖细胞毒性剂和其缀合物
WO2017093719A1 (en) Mmp-sensitive taxane prodrug
JP6817956B2 (ja) 新規なグルタミン酸誘導体とブロック共重合体を含有する組成物及びその用途
CA3126574A1 (en) Cd44 targeted multi-arm conjugate
HK40111022A (zh) 水溶性前药、偶联物及其用途
TW202325273A (zh) 靶向fap之中子捕獲劑及與其相關之用途及調配物
WO2025261479A1 (zh) 以丁二酰基为连接链的偶联物及其制备方法和用途
KR20240016231A (ko) 신규 오리스타틴 전구약물
TW201691B (https=)

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251014